Drug Profile
Research programme: antisense therapies - AstraZeneca/Ionis Pharmaceuticals
Alternative Names: ISIS 581088Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer AstraZeneca; Ionis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides; Cardiovascular therapies
- Mechanism of Action Androgen receptor antagonists; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Kidney disorders; Metabolic disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Oct 2018 Preclinical trials in Metabolic disorders in USA (unspecified route) before October 2018